Updated:
Forge Therapeutics
Forge Therapeutics (now Blacksmith Medicines) develops metalloenzyme-targeted medicines. No public data on leadership, funding, or operations available.
Forge Therapeutics
Purpose-Built Platform for Metalloenzyme-Targeted Medicines Purpose-Built Platform for Human Metalloenzyme-Targeted Medicines
General information
Firm type
other
Location
Region
North America
Country
United States
City
Pasadena, Palo Alto, Hamburg, Boston, San Diego, Houston, Cambridge, Mississauga, Indianapolis
Sector focus
Frequently asked questions
Who runs investment decisions at Forge Therapeutics?
Forge Therapeutics has not publicly disclosed its leadership team or investment decision-makers. The firm's website does not list any executives or principals as of the latest available information.
How does Forge Therapeutics source proprietary deal flow?
No information about deal flow sourcing is publicly available. The firm's website does not describe its investment process or deal origination methods.
Does Forge Therapeutics participate in fund commitments or only direct deals?
No public information exists on whether Forge Therapeutics makes fund commitments or direct investments. The firm's investment approach is not described in available sources.
Which sectors does Forge Therapeutics explicitly avoid?
Forge Therapeutics has not published any excluded sectors. The firm's website centers on metalloenzyme-targeted human medicines, but avoidance criteria are not disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: